About the Event
Immunicom has developed a hybrid cancer therapy which combines the best of a medical device with targeted drug therapy.
This revolutionary therapeutic platform delivers the drugs via a proprietary external extraction cartridge connected to existing plasma filtration equipment in oncology infusion centers. Immunicom is approved in Europe (CE Mark) for Triple Negative Breast Cancer and received FDA Breakthrough Technology Designation as a Class 3 PMA which streamlines the approval process in the U.S.
Join our webinar with Immunicom CEO, Amir Jafri, whose experience leading business development for Cardinal Health gives the company great insights into commercialization options in the very near future.